Adial Pharmaceuticals, Inc. ADIL

I’m gonna wait for a lower price to get in later

Bought this at $1.15 and I sold it for $2.51. Glad I did.

The stock is under valued what is going on ?

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder, or AUD, in heavy drinking patients and was recently investigated in the company's ONWARD pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the company's proprietary companion diagnostic genetic test. The company is also developing adenosine analogs for the treatment of pain and other disorder

April 11

Leap Therapeutics announced it has entered into a securities purchase agreement with a select group of institutional investors to issue and sell an aggregate of 12.66M shares of its common stock at a price of $2.82 per share and pre-funded warrants to purchase 1.52M shares of common stock at a price of $2.819 per share of common stock issuable upon exercise of the pre-funded warrants, in a private placement. Leap anticipates the gross proceeds from the private placement will be approximately $40M, before deducting any offering-related expenses. The financing is expected to close on April 15, subject to satisfaction of customary closing conditions. The private placement investors included new and existing investors, including Gilead Sciences, Samsara BioCapital, 683 Capital Partners, LP, Laurion Capital Management, and Rock Springs Capital. J.P. Morgan acted as the exclusive placement agent for the transaction.

That’s why it’s not moving it’s gonna go sky rocket ????????
According to TipRanks.com, McCarthy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -13.9% and a 31.9% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Genenta Science SpA Sponsored ADR, Lipella Pharmaceuticals, Inc., and SELLAS Life Sciences Group.

Currently, the analyst consensus on Adial Pharmaceuticals is a Moderate Buy with an average price target of $26.00.

Give everyone little vodka so they can move up ???????

Come on push it up it can go to 6$

Brookline Capital Reiterates Buy on Adial Pharmaceuticals, Maintains $6 Price Target
Benzinga
·
Jul 12, 2023 05:59
1min
Adial Pharmaceuticals (ADIL.US)
1.130
2.250
+0.00%
+99.12%

Brookline Capital analyst Kumaraguru Raja reiterates Adial Pharmaceuticals (NASDAQ:ADIL) with a Buy and maintains $6 price target.

Disclaimer